BCRX
BioCryst Pharmaceuticals, Inc.
BCRX's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over BCRX overall, supported by stronger fundamentals and stronger modeled upside.
BCRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Strong | |
| Strong |
BCRX's revenue, cash flow and balance sheet are currently healthy, but its profitability is weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BCRX PE Valuation
BCRX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BCRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for BCRX, with profitability improving. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
BCRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.66 | — |
| Q3 2026 | -$1.41 | -$1.36 |
| Q2 2026 | -$1.49 | -$1.31 |
| Q1 2026 | -$1.77 | -$1.51 |
| Q4 2025 | $1.21 | +$1.64 |
| Q3 2025 | -$0.05 | +$0.56 |
| Q2 2025 | -$0.18 | +$0.55 |
| Q1 2025 | -$0.26 | +$0.81 |
| Q4 2024 | -$0.43 | +$0.75 |
BCRX lost $1.41 per share over the past year, a bigger loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BCRX on earnings quality, reporting a profit while its opponent remains loss making.
BCRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $180.3M | +13% |
| Q2 2026 | $218.3M | +34% |
| Q1 2026 | $156.4M | +7.5% |
| Q4 2025 | $406.6M | +209% |
| Q3 2025 | $159.4M | +36% |
| Q2 2025 | $163.4M | +49% |
| Q1 2025 | $145.5M | +57% |
| Q4 2024 | $131.5M | +41% |
BCRX's revenue has grown year over year for 23 quarters in a row: $180M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +11 points |
| Q2 2026 | 45% | +27 points |
| Q1 2026 | -449% | -463 points |
| Q4 2025 | 64% | +68 points |
| Q3 2025 | 19% | +12 points |
| Q2 2025 | 18% | +10 points |
| Q1 2025 | 15% | +30 points |
| Q4 2024 | -3.4% | +42 points |
BCRX's operating margin was 30% last quarter, up 11 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BCRX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BCRX on profitability, with a higher operating margin.
BCRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.8M | -19% |
| Q2 2026 | $104.1M | +153% |
| Q1 2026 | -$62.2M | -$34.5M |
| Q4 2025 | $291.2M | +$297M |
| Q3 2025 | $40.3M | +392% |
| Q2 2025 | $41.1M | +$42.6M |
| Q1 2025 | -$27.7M | +$26.3M |
| Q4 2024 | -$5.9M | +$3.6M |
BCRX has burned cash in most quarters: $366M over the past year, about eight times what it generated the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
BCRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.5M shares |
| 1 year | +22% | +47.7M shares |
| 3 years | +41% | +78M shares |
| 5 years | +51% | +90.3M shares |
| Available history | +74% | +113M shares |
BCRX has 268M diluted shares, up 22% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BCRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BCRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 6.1x | High |
BCRX has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BCRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.7 | Neutral |
| Stochastic | 16.2 | Oversold |
BCRX's weekly RSI is 43 (neutral) and its Stochastic is 16 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BCRX PE vs Healthcare Sector
BCRX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BCRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.07 | 4.8% below |
| 20 week MA | $8.89 | 14% below |
| 50 week MA | $8.50 | 9.6% below |
| 100 week MA | $8.38 | 8.4% below |
| 200 week MA | $7.71 | 0.4% below |
BCRX is in a downtrend: it's below all five of its weekly moving averages, and 0.4% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BCRX on trend strength, trading above more of its moving averages.
BCRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.12 | $7.28 | +133% |
| 2021 | $7.28 | $13.9 | +91% |
| 2022 | $13.9 | $11.5 | -18% |
| 2023 | $11.5 | $5.99 | -48% |
| 2024 | $5.99 | $7.71 | +29% |
| 2025 | $7.71 | $7.63 | -1% |
| 2026 YTD | $7.63 | $7.68 | +0.7% |
BCRX's yearly returns have swung widely, from +133% in 2020 to −48% in 2023. It's up 0.7% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BCRX on returns for 2026, with the stronger performance.